Business
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
CONCORD, Calif., April 27, 2026--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device.
About this update from Cerus Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/8ba9b55ec9b1d96295fca3ede4671ef0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qN8mYORo8C0Br2UNB5w_oA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/8ba9b55ec9b1d96295fca3ede4671ef0","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/1Z34veulnTuv50VTZFkaYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/8ba9b55ec9b1d96295fca3ede4671ef0","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CONCORD, Calif., April 27, 2026--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device.","length":397,"tagName":"p"},{"type":"text","content":""We are proud to announce a new four-year supply agreement with the French Blood Establishment," said Christian Boutemy, Cerus’ vice president of international commercial operations. "EFS has been a global leader in the adoption of pathogen inactivation technologies to help safeguard the blood supply and enhance patient safety. This agreement further underscores our shared, enduring commitment to ensuring safe transfusions for patients."","length":461,"tagName":"p"},{"type":"text","content":"The EFS distributes approximately 330,000 units of platelets annually across 13 regional centers in continental France and overseas territories. The INTERCEPT Blood System for platelets has been used in France since 2006, with broader nationwide adoption following a nationwide rollout in 2017. INTERCEPT is also used throughout French overseas territories, including La Réunion, Guadeloupe, and Martinique. Implementation in those island territories was driven by the need to maintain a safe platelet supply during outbreaks of chikungunya, dengue and Zika in these tropical regions.","length":584,"tagName":"p"},{"type":"text","content":"ABOUT CERUS","length":11,"tagName":"...